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Abstract
More than 90% of children in Africa are infected with cytomegalovirus (CMV) by the age of
12 months. However, the high-frequency, immunodominant CD8+ T-cell responses that
control CMV infection have not been well studied in African populations. We therefore
sought to define the immunodominant CMV-specific CD8+ T-cell responses within sub-
Saharan African study subjects. Among 257 subjects, we determined the CD8+ T-cell
responses to overlapping peptides spanning three of the most immunogenic CMV
proteins, pp65, IE-1 and IE-2, using IFN-γ ELISpot assays. A bioinformatics tool was used
to predict optimal epitopes within overlapping peptides whose recognition was statistically
associated with expression of particular HLA class I molecules. Using this approach, we
identified 16 predicted novel CMV-specific epitopes within CMV-pp65, IE-1 and IE-2. The
immunodominant pp65-specific, IE-1, IE-2 responses were all either previously well charac-
terised or were confirmed using peptide-MHC tetramers. The novel epitopes identified
included an IE-2-specific epitope restricted by HLA*B*44:03 that induced high-frequency
CD8+ T-cell responses (mean 3.4% of CD8+ T-cells) in 95% of HLA-B*44:03-positive sub-
jects tested, in one individual accounting for 18.8% of all CD8+ T-cells. These predicted
novel CMV-specific CD8+ T-cell epitopes identified in an African cohort will facilitate future
analyses of immune responses in African populations where CMV infection is almost univer-
sal during infancy.
PLOS ONE | https://doi.org/10.1371/journal.pone.0189612 December 12, 2017 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Malik A, Adland E, Laker L, Kløverpris H,
Fardoos R, Roider J, et al. (2017)
Immunodominant cytomegalovirus-specific CD8+
T-cell responses in sub-Saharan African
populations. PLoS ONE 12(12): e0189612. https://
doi.org/10.1371/journal.pone.0189612
Editor: Naglaa H. Shoukry, Centre de recherche du
CHUM, CANADA
Received: July 16, 2017
Accepted: November 29, 2017
Published: December 12, 2017
Copyright: © 2017 Malik et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by the
Wellcome Trust (WT104748MA) and National
Institutes of Health (NIH RO1 AI46995) to PJRG.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Introduction
Human cytomegalovirus (CMV) is a ubiquitous beta human herpesvirus. The prevalence of
CMV infection is very high in developing countries [1] [2] and is endemic in sub-Saharan Afri-
can populations with almost two-thirds of infants infected by 3 months of age and 85% infected
by a year [3]. By adolescence CMV infection is virtually universal in sub-Saharan Africa [1].
CMV infection is usually asymptomatic but can lead to severe clinical complications in
patients who are immunocompromised [4–6]. We focus here on the CMV-specific CD8+ T-
cell response, since firstly, T-cell immunity plays an important role in controlling CMV infec-
tion [7] and preventing symptomatic, disseminated CMV disease [8–10] and secondly, the fre-
quency of CMV-specific T-cell responses is unusually high, on average 10% of the CD4+ and
CD8+ T-cell memory compartments in adult peripheral blood [11]. High magnitude CMV-
specific T-cell responses have also been demonstrated in infancy [12].
Although the prevalence of CMV is high in sub-Saharan African populations from infancy,
most previous studies defining CMV-specific CD8+ T-cell epitopes have focused on human
leukocyte antigen (HLA) class I alleles that are common in white populations [13–18]. The
aim of this study was therefore to identify the immunodominant CMV-specific CD8+ T cell
epitopes in a study cohort of African subjects. In order to achieve this, we determined in >250
Southern African individuals the ex vivo responses by Interferon gamma (IFN-γ) enzyme-
linked immunospot (ELISpot assay) to a panel of overlapping peptides spanning the pp65,
72-kDa immediate early (IE-1) and 86-kDa immediate early (IE-2) CMV proteins. These
have previously been shown to be three of the most immunogenic CMV proteins [11] and are
important for the structural assembly and replicative capacity of the virus [19].
We used a combination of ELISpot assays, peptide-HLA class I binding studies, bioinfor-
matic prediction and peptide-HLA-Class I tetramer studies to predict and confirm novel
CD8+ T cell epitopes in CMV. In this way, we have determined the immunodominant CMV-
specific CD8+ T-cell responses in a Southern African cohort and defined 16 novel predicted
CMV-specific CD8+ T-cell epitopes within pp65, IE-1 and IE-2, in three cases confirming the
optimal epitope and HLA restriction using peptide-HLA class I tetramers.
Material and methods
Study subjects
We studied 257 HIV-infected ART-naive adult and paediatric subjects recruited via three pre-
viously described cohorts (Table 1):
1. Kimberley, South Africa, n = 69 [20]
2. Durban, South Africa, n = 84 [21]
3. Thames Valley cohort (southern African subjects attending outpatient HIV clinics in the
Thames Valley area of the U.K, originating from Botswana, Malawi, South Africa, Kenya,
Zambia and Zimbabwe), n = 104 [22].
In total, we used 62 paediatric (all from the Kimberley cohort) and 195 adult subject sam-
ples for ELISpot studies. We used an additional 37 subject samples from Durban cohort for
NW8-tetramer staining. The samples were collected between 2009–2014. HIV viral load was
measured using the Roche Amplicor version 1.5 assay according the manufacturer’s instruc-
tions; CD4+ T-cell counts were measured by flow cytometry. The CD4% is calculated as the
percentage of live CD3+ CD4+ T-cells in total lymphocytes. The CD4% percentages in chil-
dren were recorded at the recruitment site.
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HLA typing
DNA extraction was performed from whole blood using PureGene reagents (Qiagen, UK).
Four-digit high resolution Sequence Based Typing of HLA-A, -B, and -C was performed from
genomic DNA in the CLIA/ASHI accredited laboratory of William Hildebrand, PhD, (ABHI)
at the University of Oklahoma Health Sciences Centre using a locus specific PCR amplification
strategy and a heterozygous DNA sequencing methodology for exon 2 and 3 of the class I PCR
amplicon. Relevant ambiguities [23] were resolved by homozygous sequencing.
We HLA-A/B/C typed 212 individuals, and in addition determined HLA-B-typing only on
an additional 45 individuals.
IFN-γ-ELISpot assay
Ex vivo CMV-specific CD8+ T-cell responses were screened in IFN-γ ELISpot assays using a
panel of 401 overlapping 15-mer peptides (OLP), spanning the pp65, IE-1 and IE-2 region of
CMV (OLP sequences available in S2 Table). IE-1 and IE-2 share part of their amino acid
sequence; peptides 139–158 in IE-1 are identical to peptides 259–278 in IE-2, respectively.
Peptides were synthesised by Schafer-N (Denmark) in powder form at>80% purity. Fol-
lowing dilution to 400 μg/ml, peptide pools were produced with each pool containing 100 μl of
11–12 separate peptides, with each peptide present in two different pools. The peptide pools
were generated as followed: 120 peptides in IE-1 making 22 pools; 143 peptides in IE-2 making
24 pools and 138 peptides in pp65 making 23 pools. A peptide was identified as reactive by
positive responses in the two corresponding pools. OLPs identified by the megamatrix
approach were then tested individually by ELISpot assay, depending on PBMC availability.
ELISpot assays were performed using sterile 96-well plates with a polyvinylidene fluoride
membrane (MiIlipore, USA). The plate was pre-coated with anti-human IFN-γ monoclonal
antibody (Mabtech, Sweden) in PBS at 1:2000 and incubated at 4˚C overnight. Prior to use,
the plate was washed 6 times with blocking buffer (1% heat-inactivated filtered foetal calf
serum in PBS) and 50 μl of R10 (RPMI-1640, 100 μ/ml penicillin, 100μg/ml streptomycin,
Table 1. Cohort characteristics.
Cohort Name/ Location Durban TVC Kimberley adults Kimberley
children
Total
Adults
Total
children
Recruitment source Antenatal
clinics
HIV
clinics
Paediatric clinics (mothers of HIV-
infected children)
Paediatric clinics All cohorts Kimberley
HIV-status Positive Positive Positive Positive Positive Positive
No of individuals 84 104 7 62 195 62
HIV viral load (RNA copies/
ml plasma)
Median 5,450 3,848 34,706 22,600 4,300 22,600
IQR 931–31,250 674–
15,934
25,559–43,853 4,028–106,084 816–2,300 4,028–
106,084
CD4 T -cell count (cells/
mm3)
Median 581 510 528 1018 540 1,018
IQR 415–699 362–615 461–622 724–1,381 396–659 724–1,381
CD4 T-cell % Median n/a n/a n/a 27% n/a 27
IQR n/a n/a n/a 22%-30% n/a 22–30%
Age Median 26 n/a n/a 6 n/a 6
IQR 23–30 n/a n/a 3–7 n/a 3–7
Ethics approval was given by the KwaZulu-Natal Review Board (Durban cohort); University of the Free State Ethics Committee, Bloemfontein (Kimberley
Cohort) and the Oxford Research Ethics Committee (Durban, Kimberley and Thames Valley cohorts).
All adult subjects, or parents/guardians for children, provided written informed consent for participation.
https://doi.org/10.1371/journal.pone.0189612.t001
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2mM L-Glutamine, 10% heat-inactivated filtered foetal calf serum) was added to each well.
Peptides were added to a final concentration of 40 μg/ml per well. Each plate contained two
positive controls with 250 μg/ml of CMV lysate (Virusys) and four negative controls with no
peptide/CMV lysate. Frozen PBMCs were thawed and 1x105 were added per well. The plate
was incubated for 14–16 hours in a humidified incubator at 37˚C 5%CO2. After 6 washes with
PBS, biotinylated anti-IFN-γ-antibody (Mabtech, Sweden) in PBS at 1:2000 was added and
incubated at room temperature for 90 minutes in the dark. The plate was washed 6 times with
PBS, incubated with streptavidin-alkaline phosphatase conjugate (Mabtech, Sweden) in PBS at
1:2000 for 45 minutes at room temperature in the dark. The plate was washed as before and
developed using substrate colour solution (Bio-Rad laboratories, UK). Spots were counted
using an automated ELISpot reader (AID ELISpot v4.0, Autoimmun Diagnostika, Germany).
Background (>3 standard deviations above the mean of the 4 wells containing PBMC without
a peptide) was subtracted from values of all wells, and the final result was expressed as the
number of spot-forming cells (SFC) per 106 PBMC. Positive responses were considered >100
SFC/106 PBMC after background subtraction.
Tetramer staining
Peptide-MHC tetramers were generated as previously described [24]. Cryopreserved PBMC (1
million per stain or less depending on availability) from the recipient were stained with PE-
conjugated or APC-conjugated peptide-MHC tetramers, anti-CD3 Pacific Orange (Invitrogen,
UK), anti-CD8 V450 (BD Biosciences, UK) antibodies and near-IR Live/Dead marker (Invi-
trogen, UK). Samples were analysed using an LSRII flow cytometer (BD, UK) collecting a min-
imum of 500,000 events and gating on singlets, lymphocytes, live cells and CD3+ CD8+ cells.
Data were analysed using FlowJo version 10.0.7.
Epitope prediction using HLA-Restrictor—A tool for prediction of HLA
restriction elements and optimal epitopes within peptides
The HLA-Restrictor prediction tool [25] was employed to predict the epitopes within the OLPs
with a significant HLA restriction. As input it requires four-digit HLA typing and the amino
acid sequence of the overlapping 15mer peptide in question. It then predicts the peptide-MHC
binding avidity for all possible 8-11mer peptides within the 15mer and on this basis, calculates
the likelihood of the optimal epitope.
Statistical analysis
Analysis was performed using Graph-Pad Prism v5.0c (GraphPad Software, Inc.).
Associations between peptide recognition and expression of particular HLA class I mole-
cules were calculated with Fisher’s exact test using a 2x2 contingency table (p values shown in
Tables 2 and 3). In order to correct for multiple comparisons, the Bonferroni correction was
applied to give a p value threshold of 0.0009 (calculated as the uncorrected p value of 0.05
divided by the number of HLA class I alleles being studied, n = 55).
Results
Immunodominant CMV-specific CD8+ T-cell responses within pp65, IE-
1 and IE-2
All but two of the 257 HIV-infected subjects studied made responses to one or more of the
three CMV proteins tested. The proportion of the individuals studied who showed responses
to each of the three proteins tested was 98% for pp65 (n = 152), 82% for IE-1 (n = 95) and 64%
Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations
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for IE-2 (n = 92) (Fig 1A). Fig 1B–1D show the overlapping peptides that were targeted by
more than 4% of individuals tested for pp65 and more than 3% of individuals tested for IE-1
and IE-2. Within each protein, certain 15mer overlapping peptides were immunodominant:
within pp65, two peptides were recognised by 23% of the study population (pp65 OLP-66, and
Table 2. HLA associations with the most targeted 15-mer OLP’s in CMV pp65, IE-1 and IE-2.
Protein OLP Sequence HLA association p value (Fisher’s) Predicted optimal Described/ Novel
pp65 66/67 QPFMRPHERNGFTVL B*07:02 <0.0001 RPHERNGFTVL Described26
RPHERNGFTVLCPKN B*42:01 <0.0001 RPHERNGFTVL Novel
pp65 123/124 AGILARNLVPMVATV A*02:01 <0.0001 NLVPMVATV Described26
ARNLVPMVATVQGQN
IE-1 215/216 LSEFCRVLCCYVLEE C*07:02 <0.0001 CRVLCCYVL Described27
CRVLCCYVLEELTSVM
IE-2 342/343 LDNEKVRNIMKDKNT A*30:01 <0.0001 KVRNIMKDK Novel
KVRNIMKDKNTPFCT
The table shows the epitopes that were identified in our preliminary investigation using only the most immunogenic OLPs (OLP 66/67, OLP123/124,
OLP215/216, OLP 342/343) in each protein. We identified two novel epitopes, for which we show FACS plots in Fig 2. Three epitopes have been previously
described [26,27].
https://doi.org/10.1371/journal.pone.0189612.t002
Table 3. HLA associations with the remaining 15-mer OLP’s in CMV pp65, IE-1 and IE-2 that were targeted by4% of the study cohort.
Protein OLP Sequence HLA association p value (Fisher’s) Predicted optimal Described/ Novel
pp65 4 SVLGPISGHVLKAVF B*81:01 <0.0001 GPISGHVL Novel
pp65 4 SVLGPISGHVLKAVF B*39:10 <0.0001 GPISGHVL Novel
pp65 30 PLKMLNIPSINVHHY B*35:01 <0.0001 IPSINVHHY Described29
pp65 46/47 YYTSAFVFPTKDVAL A*02:05 <0.0001 FVFPTKDV Novel
pp65 AFVFPTKDVALRHW
pp65 52 VCSMENTRATKMQVI C*06:02 <0.0001 TRATKMQVI Described30
pp65 53/54 ENTRATKMQVIGDQY A*30:02 <0.0001 KMQVIGDQY Novel
pp65 ATKMQVIGDQYVKVY
pp65 104/105 TERKTPRVTGGGAMA B*07:02 <0.0001 TPRVTGGGAM Described31
pp65 TPRVTGGGAMAGAST
pp65 131 YRIFAELEGVWQPAA B*45:01 0.0008 AELEGVWQPA Novel
IE-1 163 RHRIKEHMLKKYTQT A*30:01 0.001 RIKEHMLKKY Novel
IE-1 186 LQAKARAKKDELRRK A*74:01 <0.0001 LQAKARAKK Novel
IE-1 187 ARAKKDELRRKMMYM B*08:01 <0.0001 ELRRKMMYM Described32
IE-1 187/188 ARAKKDELRRKMMYM B*18:01 <0.0001 DELRRKMMY Novel
IE-1 KDELRRKMMYMCYRN
IE-1 200 EIMAYAQKIFKILDE A*23:01 0.0004 AYAQKIFKI Novel
IE-1 212/213 ACMMTMYGGISLLSE B*42:01 <0.0001 TMYGGISLL Novel
IE-1 TMYGGISLLSEFCRV
IE-1 226 KVFAQYILGADPLRV C*07:02 <0.0001 QYILGADPL Novel
IE-1 233 ESDEEEAIVAYTLAT B*35:01 0.0007 EAIVAYTL Novel
IE-1 234 EEAIVAYTLATAGVS B*40:02 0.001 EEAIVAYTL Novel
IE-2 374/375 TADACNEGVKAAWSL B*44:03 <0.0001 NEGVKAAW Novel
CNEGVKAAWSLKELH
The table shows additional predicted epitopes identified using the remaining 15mer peptides that were targeted by4% of the study cohort. We identified
an additional 14 novel predicted epitopes, and four previously published [29–32] epitopes.
https://doi.org/10.1371/journal.pone.0189612.t003
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OLP-123), within IE-1, one 15mer was recognised by 17% of the study cohort (IE-2 OLP-215),
and within IE-2, one 15mer was recognised by 10% of the subjects studied (IE-1 OLP-343)
(Fig 1B–1D). The OLPs adjacent to immunodominant ones were also recognised, and the
majority of the subjects making a response to these were within the group who recognised
Fig 1. Immunodominant CMV-specific CD8+ T-cell responses within pp65, IE-1 and IE-2 measured by IFN-g ELISpot assay for CMV
+ subjects. (A) Percentage responders to each protein-covering peptide pool. (B) Percentage responders among 152 CMV+ individuals to pp65
15mer overlapping peptides that were targeted by >4% of the study population. (C) Percentage responders among 95 CMV+ individuals to IE-1 15mer
overlapping peptides that were targeted by >3% of the study population. (D) Percentage responders among 92 CMV+ individuals to IE-2 15mer
overlapping peptides that were targeted by >3% of the study population.
https://doi.org/10.1371/journal.pone.0189612.g001
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immunodominant OLPs. For example, 70% of the individuals responding to OLP-67 also
responded to OLP-66, 88% of the individuals responding to OLP-124 also responded to OLP-
123, 92% of the individuals responding to OLP-216 also responded to OLP-215 and 50% of
the individuals responding to OLP-342 also responded to OLP-343. Recognition of two adja-
cent OLPs indicates the location of the 8-11mer optimal epitope, at least in part, within both
15mers.
Recognition of these 15mers in the ELISpot assays was in each case strongly associated with
expression of particular HLA class I molecules (Table 2). An epitope predictor tool HLA-Res-
trictor [25] was then used to predict the optimal epitope from within the 15mers that would be
presented by the relevant HLA class I molecule. This yielded 3 well-characterised and previ-
ously described epitopes [26,27] including the HLA-A02:01-restricted epitope NLVPMVATV
[26] and the HLA-B07:02-restricted epitope RPHERNGFTVL[26], both in pp65. Two novel
epitope candidates emerged also from this analysis, an HLA-B42:01-restricted epitope
RPHERNGFTVL in pp65 and an HLA-A30:01-restricted epitope KVRNIMKDK within IE-2.
The respective peptide-MHC tetramers were synthesised and used to stain PBMC in subjects
who had shown responses to the 15mer peptides; in each case, these tetramers confirmed the
optimal epitope and the HLA restriction of the response (Fig 2). One subject per epitope was
tested with the corresponding tetramer.
This approach to defining the optimal CMV-specific epitopes within a Southern African
study cohort therefore was validated for the 15mer overlapping peptides that were best recog-
nised within the three CMV proteins studied.
Identification of additional novel CD8+ T-cell epitopes within pp65, IE-1
and IE-2
Due to the encouraging results, we decided to additionally analyse the remaining 15mer pep-
tides to which responses were observed in4% of the study cohort. This threshold was chosen
because, at<4% recognition, the number of subjects studied did not provide sufficient statisti-
cal power to detect associations between peptide recognition and expression of particular HLA
class I molecules that would remain significant (p<0.05) after correction for multiple tests
(uncorrected p value <0.0009: see Methods). In addition to the five epitopes described above
(Table 2), we identified responses to 18 predicted CMV-specific CD8+ T-cell epitopes that
were significantly associated with expression of particular HLA class I molecules (uncorrected
p<0.0009, corrected p<0.05) (Table 3). Using epitope predictor tool, we found that 14 pre-
dicted epitopes are novel and four have been previously described in the literature (Table 3).
In summary, across both experiments, we found that seven of the yielded epitopes had been
previously described and the remaining 16 predicted epitopes are novel. As might be expected,
the previously described epitopes are presented by HLA class I molecules that are highly preva-
lent in white populations whilst the novel predicted epitopes are restricted by HLA class I mol-
ecules that are in many cases broadly African-specific. The PF of the HLA alleles presenting
the CMV-specific epitopes identified in this study are shown in S1 Fig (the figure shows the PF
of HLA alleles presenting the CMV-specific epitopes in a representative white population [28]
[www.allelefrequencies.net] and our African cohort).
Closely related HLA I molecules shape distinct CMV-specific CD8+ T-
cell hierarchies
Comparison of the HLA class I molecules prevalent in white and sub-Saharan African popula-
tions in many cases reveals small differences in phenotypic frequency between the closely-
related HLA alleles. Among HLA-A02-positive white individuals, for example, 97% express
Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations
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Fig 2. Validation of novel CD8+ T-cell epitopes in CMV using HLA-Class I tetramers. (A) Flow cytometry plot of CD8+ T-cell
responses from a Durban cohort subject SK-251 (HLA-A*02:05, -A*30:01, -B*42:01, -B*58:01, -C*07:01, -C*017:01) to
HLA-A*30:01-restricted IE-2-342/343 epitope-KK9 and an HLA-mismatched tetramer stain as a control. (B) Flow cytometry plot from a
Durban cohort subject SK-331 (HLA-A*30:01, -A*66:01, -B*42:01, -B*58:02, -C*06:02, -C*017:01) to B*42:01-restricted pp65-66/67
epitope RL11 and an HLA-mismatched tetramer stain as a control. The plots show gated live CD3+ T-cells; the number shown above each
gate is the percentage of live CD3+ CD8+ cells that are tetramer-specific.
https://doi.org/10.1371/journal.pone.0189612.g002
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HLA-A02:01[28], whereas approximately 50% of HLA-A02-positive individuals in our Afri-
can cohort express HLA-A02:02 or HLA-A02:05, HLA-A02 molecules that differ by 3 and 4
amino acids, respectively, from HLA-A02:01(Fig 3A). However, it is clear from our study that
the immunodominant HLA-A02:01-restricted response is towards the pp65 OLP-123/124
peptide (NLVPMVATV), as described previously [26], whereas these data suggest that the
immunodominant HLA-A02:05-restricted response, more prevalent in Africans, is towards
the pp65 OLP-46/47 peptide (FVFPTKDV) (Fig 3B).
Fig 3. Phenotypic frequencies of closely related HLA I molecules and their impact on CMV specific CD8+ T-cell hierarchies. (A) The
phenotypic frequency of some of the HLA class I molecules in A2 superfamily in white populations [28] and our African cohort. (B) The percentage of
subjects with HLA alleles A*02:01 (n = 23), A*02:02 (n = 10) and A*02:05 (n = 16), responding to epitope (NLVPMVATV) in pp65-123/124 peptide and
predicted epitope (FVFPTKDV) in pp65-46/47 peptide. (C) The phenotypic frequency of the HLA class I molecules in B07 superfamily in white
populations [28] and our African cohort. (D) The percentage of subjects with B*07:02 (n = 21), B*35:01 (n = 10), B*39:10 (n = 6), B*42:01 (n = 26) and
B*81:01(n = 12) alleles in our African cohort responding to predicted epitopes in pp65, GPISGHVL (OLP-4), RPHERNGFTVL (OLP-66/67) and
TPRVTGGGAM (OLP-104/105). The percentage of subjects in our African cohort responding to predicted epitope in IE-1, TMYGGISLL (OLP-212/
213) with HLA-B*07:02 (n = 11), B*35:01 (n = 6) B*39:10 (n = 5), B*42:01 (n = 19) and B*81:01(n = 1) alleles.
https://doi.org/10.1371/journal.pone.0189612.g003
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Similarly, among HLA class I molecules within the B7 superfamily, only HLA-B07:02-
restricted responses have been well characterised to date. The HLA-B07:02 allele is the most
common allele in B7 superfamily [28] in white populations. There are two pp65-specific
HLA-B07:02-retricted epitopes that are both targeted by>50% of subjects expressing
HLA-B07:02. However, one of these two epitopes is clearly immunodominant among
HLA-B42:01-restricted CMV-specific responses, and neither is significantly targeted by sub-
jects expressing either HLA-B39:10, HLA-B81:01 or HLAB35:01 (Fig 3D). HLA-B39:10,
HLA-B81:01 and HLA-B35:01 alleles are part of the B7 superfamily and common African
alleles. Thus, as might be expected and shown previously in relation to other virus-specific
CD8+ T-cell responses [33] [34], the difference of even a few amino acids between closely-
related HLA class I molecules can have a substantial impact on the CD8+ T-cell immunodomi-
nance hierarchy observed.
Definition of a high frequency HLA-B*44:03-restricted IE-2-specific
response
One of the novel epitopes identified in these studies is the epitope NEGVKAAW (NW8) in
IE-2 restricted by HLA-B44:03. The responses to this epitope were unusually high, even for
CMV-specific CD8+ T-cell responses that are generally high magnitude responses, in one indi-
vidual accounting for 18.8% of CD8+ T-cells (Fig 4A). As controls, we show representative
FACS plots of a HLA-B44:03 expressing individual stained with an HLA-mismatched tetra-
mer and a non-HLA-B44:03 expressing individual stained with the NW8-tetramer (4B-C).
We tested a subset of 37 individuals from the Durban cohort with the NW8-epitope tetramer,
that were not part of the ELISpot studies. Among the 37 subjects tested, 35 (95%) made
responses above the positive threshold of>0.02% of CD8+ T-cells to this epitope, with a mean
CD8+ T-cell response of 3.4% (Fig 4D).
Discussion
The aim of this study was to define the immunodominant CMV-specific CD8+ T-cell
responses in a study cohort comprising Southern African individuals, focusing on three of the
most immunogenic CMV proteins pp65, IE-1 and IE-2. We validated some of these immuno-
dominant responses using peptide-MHC-class I tetramers. Using this approach, we have iden-
tified 16 novel CMV-specific epitopes within CMV pp65, IE-1 and IE-2. Using a population of
HIV-infected subjects, all of whom have sub-Saharan African origin, it has been possible, for
the first time, to investigate the HLA restrictions for alleles most prevalent in sub-Saharan
Africa. The resulting epitopes will underpin further understanding of CMV specific T-cell
immunity, which is of particular interest considering the high frequency of CD8+ T-cells that
recognize these epitopes.
One of the epitopes validated was an IE-2 epitope restricted by the predominantly African
allele, HLAB44:03, that induced consistently high CD8+ T cell responses in individuals
expressing HLA-B44:03, in one individual approaching 19% of their CD8+ cells. Typically,
during viral infections, the establishment of a memory T-cell population in response to an
antigen is thought to involve expansion followed by contraction into a stable pool of memory
cells, after the infection is cleared [35]. However, in CMV infection, CD8+ T-cells specific for
certain epitopes do not contract but instead are maintained at high frequencies. This increase
in CMV specific CD8+ T cell response has been termed ‘memory inflation’ [36]. ‘Memory
inflation’ is a term derived from studies of murine cytomegalovirus (MCMV) that detected
unusually high numbers of MCMV-specific CD8+ T-cells and eventual stabilization of mem-
ory CD8+ T-cells at high frequencies, in immune competent mice [36]. The underlying
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Fig 4. Individuals making CD8+ T cell responses against CMV IE-2 epitope HLA-B*44:03-NW8. (A)
Representative FACS plot of a Durban cohort subject 202-30-0064 (expressing HLA-B*44:03/B*58:01) to
HLA-B*44:03-restricted NW8 tetramer. (B) FACS plot of subject R048 (HLA-A*29:02, -A*6802, -B*15:03,
-B*44:03, -C*02:10, -C07:01) with NW8 tetramer and HLA-mismatched tetramer. (C) FACS plot of a TVC
subject R112 (HLA-A*23:01, -A*3002, -B*18:01, -B*18:01, -C*02:02, -C07:04) to HLA-B*44:03-restricted
NW8 tetramer, as B*44:03-negative control. The FACS plots show tetramer-specific cells expressed as the
percentage of live CD3+ CD8+ T-cells. (D) Percentage of live CD3+ CD8+ tetramer-specific T-cells in
individuals expressing HLA-B*44:03 measured using the B*44:03-NW8 tetramer.
https://doi.org/10.1371/journal.pone.0189612.g004
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mechanisms of memory T cell inflation in humans are not yet fully elucidated. However, one
feature described is restricted TCR usage [26][37]. We looked for evidence of memory infla-
tion in our cohort but found no association between the size of CD8+ T-cell responses in rela-
tion to the age of the individuals. This may be due to the adults in our study cohort being
relatively young (median age of 26 years).
HLA-B44:03, a common allele in African populations, forms a part of HLA-B44 super-
type family. The predominant HLA-B44 allele in white populations is HLA-B44:02.
Although these two HLA-B44 allotypes differ only at one position, residue 156 (HLA-B44:02:
156-Asp; HLA-B44:03: 156-Leu), the impact of this micropolymorphism appears to be that
HLA-B44:03 presents virtually all the peptides that are presented by HLA-B44:02, plus some
additional peptides not presented by HLA-B44:02 [38]. The one HLA-B44:02-positive sub-
ject tested made no IFN-gamma ELISpot response to the overlapping peptides containing
NW8.
These studies were undertaken in a cohort of HIV-infected African subjects, prompting the
question of whether the CMV-specific CD8+ T-cell responses might be affected. It is well
established that, at extremely low absolute CD4 count (<50 CD4 T-cells/mm3) HIV-infected
individuals are at risk of opportunistic CMV infections such as CMV retinitis [19]. However,
the HIV-infected individuals studied did not include such severely immunocompromised sub-
jects (the mean absolute CD4 count among the adults studied was 540 T-cells/mm3). Indeed,
HIV-infected subjects who are infected with CMV typically have a higher magnitude CMV
response than their HIV-uninfected counterparts [39]. For these reasons, we believe the identi-
fication of CMV-specific CD8+ T-cell epitope would not be substantially affected in such a
study cohort. Further evidence for the validity of the overall approach comes from the identifi-
cation of the previously well-characterised HLA-A02:01-restricted NLVPMVATV and the
HLA-B07:02-restricted RPHERNGFTVL epitopes [26], as described above.
Although the work presented here involves a comprehensive study of peptide immunodo-
minance against 3 CMV-encoded proteins in a large African cohort, there were some limita-
tions beyond our control. We were not able to test all subjects for all three CMV proteins due
to a lack of PBMC availability. Testing each protein for all subjects could help us identify more
novel epitopes in pp65, IE-1 and IE-2. The ELISpot assays were performed without CD8+ T-
cell enrichment so CD4+ T-cell cross reactivity with the overlapping peptides cannot be ruled
out, however, the tetramer staining for some of the epitopes is unequivocal evidence for CD8+
T-cell specificity. The HLA class I associations with recognition of particular peptides is further
evidence against these being CD4 T helper responses. A CMV negative control to test the tetra-
mers would have been desirable but it is not feasible to find a CMV negative subject in an Afri-
can cohort.
These new findings facilitate further analysis of CMV-specific CD8+ T-cell responses in
African populations where most infants are CMV-infected within the first few months of life
and approaching 90% are CMV-infected by 1 year of age. CMV is a major cause for concern
in sub-Saharan African populations, due to high prevalence of HIV infection in these popula-
tions. The immunodeficiency caused by chronic HIV infection influences the consequences
of co-infection, increasing the risk of long-term morbidity and mortality. Identification of
novel epitopes reported here that are restricted by common HLA alleles could pave the way to
immune-mediated prevention and/or therapy of CMV infection.
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molecules in our African cohort and a representative white population [28].
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S2 Table. Overlapping peptide sequences. (A) Sequences of overlapping peptides in pp65, (B)
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